Observational studyPloS one2024

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.

Shu-Yuan Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.